Niagen Bioscience (NAGE) is back on investor radars after reporting first quarter 2026 earnings, with sales of US$31.47 million and net income of US$6.32 million from continuing operations. See our ...

Q2 FY26 earnings call highlights: raised revenue guide, AI-enabled drug discovery, AWS partnership, margin and EBITDA outlook.

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will parti ...

Artisan Partners, an investment management company, released its first-quarter 2026 investor letter for the “Artisan Mid Cap ...

Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes.

Tru Niagen is expanding its patented nicotinamide riboside, known as Niagen, into skincare and beauty supplements. Driven by ...

Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the ...

(Editor’s note: This story has been updated to include NAGE stock movement) Niagen Bioscience NAGE, the maker of anti-ageing ...

Shift Bioscience, a biotech company using an AI powered virtual cell to fight age-related diseases, today announced the establishment of a new North American team and facilities to advance development ...

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and ...

The CEO of the controversial firm says the new service is possible to due its existing technology, plus increased capacity at the Wilsonville facility Earlier this week, the Wilsonville-based biotech ...

Humans wiped out the bluebuck in Africa around 200 years ago. Bringing it back is both ethically and technologically ...